Agomelatine, a novel and clinically effective antidepressant MT1 and MT2 receptors agonist and 5HT2c receptor antagonist more significantly attenuates CNS complication more significantly attenuates CNS complication such as anxiety, depression, memory dysfunction, epilepsy and other mood behaviour (obsessive compulsive disorder, migraine, sleep disorder, psychosis, parkinsonism) in rodents by acting on receptor like GABA-A, NMDA, serotonergic receptors, dopamine, cholinergic, adrenergic, CRF receptor. Benzodiazepine drugs are widely used for the treatment of insomnia and other CNS mood behaviour. Nevertheless, their adverse effects, such as next-day hangover, dependence and impairment of memory, make them unsuitable for long-term treatment. Melatonin analogue has been used for improving sleep and circadian rhythm in patients with mood disorder mainly because it does not cause hangover or show any addictive potential. However, there is a lack of consistency on its therapeutic value (partly because of its short half-life and the small quantities of melatonin employed). Thus, attention has been focused either on the development of more potent melatonin analogs with prolonged effects or on the design of slow release melatonin preparations. Agomelatine is a novel melatonergic and serotonergic antidepressant attenuates CNS complication by restores disrupted biological rhythms, essentially by resetting the circadian clock also antioxidant activity of agomelatine showed in the prefrontal cortex, striatum and hippocampus of swiss mice.
Loading....